Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | pDCs | -0.86507 | 1.07e-12 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | -1.1409 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Plasma cells | -1.18763 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | CD8+ T cells | -0.676471 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Mono/Macro | -1.15714 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Mast cells | -0.633461 | 2.90e-04 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | NK cells | -0.682626 | 1.91e-08 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | B cells | -0.31508 | 1.45e-24 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Malignant cells | -0.902366 | 7.74e-17 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | CD4+ T cells | -0.696582 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
SCGB1A1 | transfac_pro__M06539 | ZNF483 (directAnnotation). |
SCGB1A1 | jaspar__MA1154.1 | ZNF282 (directAnnotation). |
SCGB1A1 | taipale__GMEB2_DBD_WRCGTAACCACGYN_repr | GMEB2 (directAnnotation). |
SCGB1A1 | hdpi__FLI1 | FLI1 (directAnnotation). |
SCGB1A1 | dbtfbs__ZNF660_HEK293_ENCSR283DOU_merged_N1 | ZNF660 (directAnnotation). |
SCGB1A1 | transfac_pro__M06487 | ZNF695 (directAnnotation). |
SCGB1A1 | kznf__ZNF418_Imbeault2017_RP_ChIP-seq | ZNF418 (directAnnotation). |
SCGB1A1 | transfac_pro__M06756 | ZNF646 (directAnnotation). |
SCGB1A1 | taipale_tf_pairs__CEBPG_CREB3L1_NGCCACGCAAYN_CAP_repr | CEBPG; CREB3L1 (directAnnotation). |
SCGB1A1 | transfac_pro__M06292 | ZNF766 (directAnnotation). |
SCGB1A1 | hocomoco__KAISO_HUMAN.H11MO.2.A | ZBTB33 (directAnnotation). |
SCGB1A1 | metacluster_70.14 | POU2F3 (directAnnotation). |
SCGB1A1 | stark__RTAAMA | FOXC2 (inferredBy_Orthology). |
SCGB1A1 | metacluster_179.5 | MEF2A; MEF2A; MEF2A; MEF2A (directAnnotation). |
SCGB1A1 | taipale_tf_pairs__CUX1_SOX15_ATCRATNNNNNNNNSYATTGTT_CAP_repr | CUX1; SOX15 (directAnnotation). |
SCGB1A1 | metacluster_130.9 | ZNF569 (directAnnotation). ZNF569 (inferredBy_Orthology). |
SCGB1A1 | hocomoco__FOXJ3_HUMAN.H11MO.1.B | FOXJ3 (directAnnotation). |
SCGB1A1 | bergman__croc | FOXC2 (inferredBy_Orthology). |
SCGB1A1 | metacluster_56.5 | HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology). |
SCGB1A1 | metacluster_155.29 | ZNF2 (directAnnotation). ZNF2 (inferredBy_Orthology). |
SCGB1A1 | taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr | CREB1 (directAnnotation). |
SCGB1A1 | transfac_public__M00266 | FOXC2 (inferredBy_Orthology). |
SCGB1A1 | transfac_pro__M05756 | ZNF470 (directAnnotation). |
SCGB1A1 | tfdimers__MD00181 | DBP; E2F1 (directAnnotation). |
SCGB1A1 | tfdimers__MD00274 | MYCN (directAnnotation). |
SCGB1A1 | transfac_pro__M06214 | ZNF33B (directAnnotation). |
SCGB1A1 | taipale_tf_pairs__POU2F1_FOXO6_RMATATKCNNNNNNNNNNNNNRWMAACA_CAP_repr | FOXO6; POU2F1 (directAnnotation). |
SCGB1A1 | transfac_pro__M06781 | ZNF107 (directAnnotation). |
SCGB1A1 | tfdimers__MD00128 | CDX2; PDX1 (directAnnotation). |
SCGB1A1 | transfac_pro__M05868 | ZNF491 (directAnnotation). |
SCGB1A1 | transfac_pro__M06162 | ZNF93 (directAnnotation). |
SCGB1A1 | transfac_pro__M06413 | ZNF573 (directAnnotation). |
SCGB1A1 | tfdimers__MD00394 | CDX2; PAX4 (directAnnotation). |
SCGB1A1 | transfac_pro__M06754 | ZBTB39 (directAnnotation). |
SCGB1A1 | cisbp__M02748 | NFATC1 (directAnnotation). |
SCGB1A1 | transfac_pro__M05779 | ZNF674 (directAnnotation). |
SCGB1A1 | transfac_pro__M05613 | ZNF35 (directAnnotation). |
SCGB1A1 | transfac_pro__M04699 | MAFK (directAnnotation). |
SCGB1A1 | metacluster_22.21 | NFE2L2 (inferredBy_Orthology). |
SCGB1A1 | taipale_tf_pairs__HOXB2_PAX5_NNMATTAGTCACGCWTSRNTG_CAP | HOXB2; PAX5 (directAnnotation). |
SCGB1A1 | dbtfbs__NCOA3_MCF-7_ENCSR573OJP_merged_N2 | NCOA3 (directAnnotation). |
SCGB1A1 | taipale_tf_pairs__MYBL1_ELF1_NMCCGGAACCGTTR_CAP_repr | ELF1; MYBL1 (directAnnotation). |
SCGB1A1 | kznf__CTCF_Rhee2011.3_ChIP-exo | CTCF (directAnnotation). |
SCGB1A1 | metacluster_21.5 | HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology). |
SCGB1A1 | transfac_pro__M05465 | SNAI3 (inferredBy_Orthology). |
SCGB1A1 | transfac_pro__M06499 | ZNF383 (directAnnotation). |
SCGB1A1 | transfac_pro__M05609 | SALL3 (directAnnotation). |
SCGB1A1 | transfac_pro__M06408 | ZSCAN30 (directAnnotation). |
SCGB1A1 | metacluster_56.4 | HSF1; HSF2; HSF2; HSF4 (directAnnotation). |
SCGB1A1 | transfac_pro__M05915 | ZBTB20 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |